Showing results (21-30 of 180) with videos related to
Sort By:
Pageof 18
Protein Engineering, Design & Selection : PEDS|September 4, 2012
Improved drug-like properties of therapeutic proteins by directed evolutionAndrew Buchanan, Franco Ferraro, Steven Rust, et al.British Journal of Clinical Pharmacology|June 22, 2018
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 studyPhilip D Ambery, Sebastian Klammt, Maximillian G Posch, et al.Endocrinology, Diabetes & Metabolism|March 1, 2019
Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes statusEllen Berni, Nicholas Pritchard, Sara Jenkins-Jones, et al.Mabs|August 29, 2012
Tailored amino acid diversity for the evolution of antibody affinityAndrea González-Muñoz, Evert Bokma, Desmond O'Shea, et al.Proceedings of the National Academy of Sciences of the United States of America|December 17, 2008
A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactionsChristian Grütter, Trevor Wilkinson, Richard Turner, et al.Plos One|August 29, 2019
Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes statusCraig J Currie, Ellen R Berni, Thomas R Berni, et al.Protein Engineering, Design & Selection : PEDS|May 21, 2011
A variant human IgG1-Fc mediates improved ADCCRoss Stewart, George Thom, Michaela Levens, et al.Peptides|September 1, 2019
Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptorDuuamene Nyimanu, Rhoda E Kuc, Thomas L Williams, et al.Journal of Immunological Methods|March 22, 2005
Affinity maturation of a V(H)H by mutational hotspot randomizationKerrm Y F Yau, Ginette Dubuc, Shenghua Li, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With FibrosisSudha S Shankar, Samuel J Daniels, Darren Robertson, et al.Pageof 18